Largest changes in influenza vaccine rates, Pre- vs. Post-COVID-19. by Tyler B. Nofzinger (21560244)

Subjects:

Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses by Jing Wang (6206297)

“…However, how global land use changes impact soil N supply and potential N loss remains elusive. By compiling a global data set of 1,782 paired observations from 185 publications, we show that land use conversion from natural to managed ecosystems significantly reduced NNM by 7.5% (−11.5, −2.8%) and increased NN by 150% (86, 194%), indicating decreasing N availability while increasing potential N loss through denitrification and nitrate leaching. …”

Wetlands over the lowland Amazon basin from the Hess product [19,20]. by Nic Gedney (19762301)

Subjects:

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Association between flavonoid intakes and metabolic dysfunction-associated steatotic liver disease (MASLD) using a Restricted Cubic Spline regression model, adjusted for age, sex,... by Yuwei He (1565941)

Subjects:

The top 10 putative metabolites with the largest negative fold change between normal and thin cows. by Bhuripit Saraphol (20855573)

The top 10 putative metabolites with the largest positive fold change between normal and thin cows. by Bhuripit Saraphol (20855573)

a Non-reducing SDS-PAGE of test samples and by Vanessa Radtke (1674097)

Yeast encapsulation of a PSI can decrease the phototoxicity against microorganisms and increase the phototoxicity against mosquito larvae. by Cole J. Meier (17377064)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

(A) The incidence of OME in the VA group compared to the non-VA group. (B) The rate of tympanostomy tube insertion in the VA group and non-VA group. by Miki Kashiwagi (21439684)

Additional file 8 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 2 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 5 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 1 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 9 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 12 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)